Getting Wegovy Or Zepbound Through Medicare? Here's What Patients Need To Know Before Coverage Rolls Out Wednesday

Millions of Medicare beneficiaries will gain access to obesity drugs for the first time starting Wednesday under CMS’ temporary Bridge program, a federal initiative designed to expand GLP-1 obesity drug coverage for eligible seniors at a $50 monthly copay. The program marks a major shift in Medicare coverage. While Medicare Part D already covers some GLP-1 drugs for conditions such as diabetes and cardiovascular disease, federal rules had long blocked coverage for obesity treatment alone. Bridge temporarily changes that through the end of 2027. How Bridge Works The program is available to Medicare beneficiaries enrolled in Part D prescription drug plans. Eligible patients include those with a body mass index (BMI) of 35 or higher, along with some patients with lower BMIs who also have obesity-related conditions such as prediabetes, prior stroke, heart attack or blocked arteries in the...